Prominent examples of this paradigm are the development of imatinib, a monoclonal antibody targeting the BCR-ABL fusion protein in chronic myelogenous leukemia1, of trastuzumab to target HER-2 over-expressing breast cancer patients2, and the use of BRAF and MEK inhibitors for the treatment of BRAF-mutant melanoma3 and of EGFR inhibitors for EGFR-mutant lung cancers4. Here, BRAF is linked to breast carcinoma.